NRD
CSTL icon

Nebula Research & Development’s Castle Biosciences CSTL Stock Holding History

Nebula Research & Development’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,472
Closed -$908K – 222
2025
Q2 		$908K Buy
44,472
+6,855
+18% +$127K 0.08% 435
2025
Q1 		$753K Buy
37,617
+10,943
+41% +$271K 0.07% 469
2024
Q4 		$711K Buy
+26,674
New +$812K 0.08% 418

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's CSTL Position: Q3 2025 in Review

Nebula Research & Development sold out of Castle Biosciences (CSTL) in Q3 2025, closing a stake of 44,472 shares — an estimated $908K sold.

Nebula Research & Development first reported a position in CSTL in Q4 2024 and held it in 3 quarters. The position peaked at $908K in Q2 2025. 173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Nebula Research & Development reported no remaining Castle Biosciences position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 44,472 Castle Biosciences shares in Q3 2025, an estimated $908K.
  • Nebula Research & Development first reported a position in Castle Biosciences in Q4 2024 and held it in 3 quarters.
  • Nebula Research & Development's Castle Biosciences position peaked at $908K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.